Glenmark launches generic Olanzapine for Injection 10 mg/vial in the US, a bioequivalent alternative to Zyprexa IntraMuscular Injection for institutional care.
Written By: Kalyani Boharapi,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection, 10 mg/vial, Single-Dose Vial, further expanding its portfolio of injectable generic medicines in the United States. The product is approved as a bioequivalent and therapeutically equivalent generic to Zyprexa® IntraMuscular Injection, 10 mg/vial, marketed by Cheplapharm Registration GmbH under NDA 021253.
The launch strengthens Glenmark’s presence in the institutional healthcare market, where injectable therapies play an important role in the emergency management of acute psychiatric conditions. According to IQVIA sales data, the US market for Zyprexa IntraMuscular Injection generated approximately $25.4 million in annual sales during the 12 months ending May 2026, highlighting a commercially established market for the product.
Clinical Background
Olanzapine is an atypical antipsychotic that acts by modulating multiple neurotransmitter receptors, including dopamine and serotonin receptors. The intramuscular formulation is used when rapid symptom control is required and oral treatment is not appropriate, particularly in patients experiencing acute agitation associated with schizophrenia or bipolar I disorder.
Acute agitation represents a psychiatric emergency that can place both patients and healthcare providers at risk. Rapid-acting intramuscular antipsychotics remain an important treatment option in emergency departments, psychiatric hospitals, and other institutional care settings, where timely symptom control can facilitate patient stabilization and reduce the need for physical restraint.
Regulatory and Product Details
Glenmark’s Olanzapine for Injection, 10 mg/vial, Single-Dose Vial received approval through the US Food and Drug Administration’s abbreviated regulatory pathway after demonstrating bioequivalence and therapeutic equivalence to the reference listed drug. These findings support its substitution for the branded product while maintaining comparable quality, safety, and clinical performance.
The launch adds another injectable medicine to Glenmark’s growing US portfolio, reflecting the company’s continued investment in complex hospital-based generic products.
Company Perspective
Marc Kikuchi, President and Business Head, North America, said the introduction of Olanzapine for Injection aligns with Glenmark’s strategy to expand its injectable medicines portfolio while strengthening its presence in institutional healthcare channels. He added that the company remains focused on improving access to high-quality, affordable treatment options for patients and healthcare providers.
Path Forward
The launch reinforces Glenmark’s broader strategy of expanding its US generic injectables business, an area that continues to offer opportunities as healthcare systems seek reliable and cost-effective alternatives to branded hospital medicines. By adding Olanzapine for Injection to its portfolio, the company further broadens access to an established psychiatric therapy while strengthening its position in the institutional pharmaceutical market.
Reference
Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single-Dose Vial
About the Writer
Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.
